glimepiride has been researched along with Parkinson Disease in 2 studies
glimepiride: structure given in first source
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oduola-Akande, MD | 1 |
| Ishola, IO | 1 |
| Olubodun-Obadun, TG | 1 |
| Akande, AJ | 1 |
| Adeyemi, OO | 1 |
| Lietzau, G | 1 |
| Magni, G | 1 |
| Kehr, J | 1 |
| Yoshitake, T | 1 |
| Candeias, E | 1 |
| Duarte, AI | 1 |
| Pettersson, H | 1 |
| Skogsberg, J | 1 |
| Abbracchio, MP | 1 |
| Klein, T | 1 |
| Nyström, T | 1 |
| Ceruti, S | 1 |
| Darsalia, V | 1 |
| Patrone, C | 1 |
2 other studies available for glimepiride and Parkinson Disease
| Article | Year |
|---|---|
Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diabetes Mellitus, Type 2; Disease Models, An | 2023 |
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
Topics: Aging; Animals; Corpus Striatum; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2020 |